2027 Pharmaceutical Companies Vaccines 
European Pharmaceutical Review
OCTOBER 12, 2023
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. The pharmaceutical company stated it will establish the first industrial-scale supply of biomethane. The Dunboyne facility is the company’s first biologics drug substance single-use commercialisation facility.
pharmaphorum
JANUARY 16, 2023
Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. The fundamental engine of innovation for the global pharmaceutical industry continues. Innovation will power the market.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ISPE
SEPTEMBER 29, 2023
For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
pharmaphorum
JANUARY 6, 2022
IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.
Pharmaceutical Technology
APRIL 24, 2023
Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. As a result, some pharmaceutical companies are turning to third parties.
Expert insights. Personalized for you.
104 
Let's personalize your content